Drugs, genes and databases for healthy ageing
Joao Pedro Magalhães
University of Liverpool, UK
Age-related conditions are the leading causes of death and healthcare costs. Reducing the rate of aging would have enormous medical and financial benefits. A large number of potential longevity-extending drugs and drugs targets already exist, yet given long validation times, only a small fraction of them can be explored for clinical applications. Therefore, prioritizing drugs and targets is imperative. In this talk, I will present network pharmacology and machine learning approaches applied to lifespan-extending compounds. I will also present DrugAge (http://genomics.senescence.info/drugs/), a curated database of lifespan-extending drugs and compounds, and its data analysis. These approaches provide insights into lifespan-extending compounds and the genes and pathways they target. They also allow us to identify and prioritize further compounds with potential geroprotector properties, which we validated experimentally.
I have no financial interests to the disclose related to the work I plan to present.
University of Liverpool, UK
Age-related conditions are the leading causes of death and healthcare costs. Reducing the rate of aging would have enormous medical and financial benefits. A large number of potential longevity-extending drugs and drugs targets already exist, yet given long validation times, only a small fraction of them can be explored for clinical applications. Therefore, prioritizing drugs and targets is imperative. In this talk, I will present network pharmacology and machine learning approaches applied to lifespan-extending compounds. I will also present DrugAge (http://genomics.senescence.info/drugs/), a curated database of lifespan-extending drugs and compounds, and its data analysis. These approaches provide insights into lifespan-extending compounds and the genes and pathways they target. They also allow us to identify and prioritize further compounds with potential geroprotector properties, which we validated experimentally.
I have no financial interests to the disclose related to the work I plan to present.
